“The studies we conduct also focus on how different vaccines compare to each other, with regard to the immune responses they generate,” Prof. Malavige further noted. According to Prof. Malavige, the studies had initially started with the AstraZeneca Covishield vaccine when it had been administered to healthcare workers in the country. However, even after 16 weeks, nearly 93.7% had antibodies, but neutralising antibodies had declined in the elderly,” Prof. Malavige noted. Furthermore, he also added that a single dose of the AstraZeneca vaccine would give approximately 33% protection, especially against the Delta variant. A single dose of any vaccine is likely to be less effective against the Delta variant, Prof. Malavige told The Sunday Morning.

Source: The Nation July 31, 2021 18:00 UTC